Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely.
Pharmacological effects of acute treatment with reboxetine (REB), a clinically active antidepressant (a noradrenaline reuptake inhibitor without any affinity for neurotransmitter receptors), were studied in mice and rats. REB inhibited the reserpine- or apomorphine-induced hypothermia in mice. It reduced the immobility time in Porsolt's test in mice and rats, but it did not change the locomotor activity in mice and rats. REB changed neither the clonidine-induced aggressiveness in mice nor the behavioral syndrome induced by oxotremorine in rats. The obtained results indicate that REB, given acutely, shows a pharmacological profile similar to that of tricyclic or tetracyclic noradrenaline reuptake inhibitors. In contrast to the antidepressants mentioned above, REB does not exhibit an alpha1-adrenolytic or cholinolytic activity (in vivo tests).